On March 25, trade regulator left the option of export open

India changed its official policy and prohibited export of Hydroxychloroquine, a drug that has uses in the treatment of COVID-19, hours before U.S. President Donald Trump urged Prime Minister Narendra Modi to release the quantity of the drug that the U.S. had ordered.

The Directorate-General of Foreign Trade (DGFT) had prohibited the export of the drug on March 25. But it left the option of export open to fulfil “export obligation” and on “humanitarian grounds”.

Also Read Hydroxychloroquine shows potential to treat COVID-19, a preprint claims

On April 4, the DGFT issued a new notification, ending the exception mentioned in the previous order. As a result, India will not export Hydroxychloroquine and formulations made from it even “against full advance payment”. “The export of Hydroxychloroquine and formulations made from Hydroxychloroquine, therefore, shall remain prohibited, without any exception,” said the notification issued by the DGFT on Saturday.

The Ministry of External Affairs did not respond to questions on the sudden change in the policy. Following Saturday’s phone conversation between the two leaders, the Ministry said Mr. Modi conveyed India’s “deep condolences” to Mr. Trump for the loss of lives in the U.S.

Also Read Trump requests PM Modi to release Hydroxychloroquine ordered by U.S.

“I’d appreciate if they would release the amounts that we ordered and they are giving it serious consideration,” Mr. Trump said about the conversation, indicating that India is holding up the export of the drug because of domestic requirements.